Evidence mapPaperPMID 41459495Full record

ReviewFrontiers in immunology2025

Unraveling the RKIP-YY1 axis: immune crosstalk in the pathogenesis of metabolic disorders.

Fawaz Alzaid, Hossein Arefanian, Fatemah Bahman, Shaima Albeloushi, Ghadeer Alhamar, Anwar Mohammad, Amal Hasan, Ashraf Al Madhoun, Rasheed Ahmad, Fahd Al-Mulla

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Fawaz AlzaidDasman Diabetes Institute, Kuwait City, Kuwait.
Hossein ArefanianDasman Diabetes Institute, Kuwait City, Kuwait.
Fatemah BahmanDasman Diabetes Institute, Kuwait City, Kuwait.
Shaima AlbeloushiDasman Diabetes Institute, Kuwait City, Kuwait.
Ghadeer AlhamarDasman Diabetes Institute, Kuwait City, Kuwait.
Anwar MohammadDasman Diabetes Institute, Kuwait City, Kuwait.
Amal HasanDasman Diabetes Institute, Kuwait City, Kuwait.
Ashraf Al MadhounDasman Diabetes Institute, Kuwait City, Kuwait.
Rasheed AhmadDasman Diabetes Institute, Kuwait City, Kuwait.
Fahd Al-MullaDasman Diabetes Institute, Kuwait City, Kuwait.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolic diseases, including obesity, type 2 diabetes, and cardiovascular disorders, are increasingly recognized as chronic inflammatory conditions driven by dysregulated immune-metabolic interactions. Two pivotal regulators of this crosstalk are Raf kinase inhibitor protein (RKIP) and the transcription factor Yin Yang 1 (YY1), which coordinate inflammatory signaling and metabolic stress responses across multiple tissues. RKIP exerts protective, anti-inflammatory effects by antagonizing the MAPK and NF-κB pathways, thereby preserving tissue homeostasis under metabolic stress. In contrast, YY1 acts as a context-dependent transcriptional regulator that promotes inflammatory gene programs, contributes to maladaptive immune cell differentiation, and exacerbates metabolic dysfunction. Notably, RKIP and YY1 are reciprocally regulated: RKIP suppresses YY1 expression via NF-κB inhibition, whereas YY1 represses RKIP transcription through a Snail-dependent feedback loop. In metabolic disease states, this balance is disrupted, RKIP is downregulated, and YY1 is upregulated, leading to heightened immune activation, cytokine production, and tissue damage. Therefore, we propose that RKIP and YY1 represent two opposing yet dynamically coordinated regulators of immunometabolic balance, functioning as a molecular rheostat that determines whether immune responses shift toward inflammation or resolution under metabolic stress. This review synthesizes current insights into the molecular structures, signaling pathways, and tissue-specific functions of RKIP and YY1, emphasizing their interplay in shaping immune responses in metabolic disorders. We further discuss emerging therapeutic approaches aimed at restoring RKIP-YY1 homeostasis to mitigate chronic inflammation and metabolic pathology.

Indexed as

Metabolic DiseasesPhosphatidylethanolamine Binding ProteinYY1 Transcription FactorAnimalsGene Expression RegulationHumansSignal TransductionPEBP1 protein, humanPhosphatidylethanolamine Binding ProteinYY1 protein, humanYY1 Transcription Factorimmunityinflammationmetabolic diseaseRKIPYY1

Identifiers

PMID41459495
PMCPMC12739478

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.